IO Biotech’s key strengths are its focused immuno‑oncology platform, the differentiated dual‑action vaccine mechanism, and a portfolio of patents across several important immune targets. The company has historically shown it can raise substantial equity, maintains low financial leverage, and still holds a meaningful, though shrinking, cash balance. Its lean, asset‑light structure means most resources are directed straight into scientific and clinical work rather than fixed infrastructure.

Major risks include the complete absence of revenue, ongoing large operating losses, and a cash runway that currently extends only into early 2026. The failure of the pivotal melanoma study for its lead asset has increased clinical and strategic uncertainty, potentially making future fundraising or partnering more difficult. Competition in cancer vaccines and immunotherapies is intense, with larger, better‑funded players pursuing overlapping targets and approaches. The strategic review itself introduces additional uncertainty about the company’s future shape, governance, and control.

Near‑term, IO Biotech’s trajectory will likely be driven more by corporate events and financing outcomes than by incremental financial performance. The strategic review could lead to partnerships, a sale, asset divestitures, or cost‑cutting, and the timing is constrained by the finite cash runway. Medium‑term prospects hinge on whether upcoming clinical data from Cylembio combinations and early pipeline assets can restore confidence in the T‑win platform. Overall, the outlook combines meaningful scientific upside potential with high operational and financial uncertainty, typical of a late‑stage but cash‑constrained biotech at an inflection point.